Medincell Sa · EURONEXT:MEDCL
Medincell Sa — Corporate Update (October 2026)
17 slides from Medincell Sa's corporate update, Oct 9, 2026
Slide 1: WELTRUZA (Olanzapine LAI) U.S. FDA Approval, A New Growth Chapter for Medincell
WELTRUZA (Olanzapine LAI) U.S. FDA Approval, A New Growth Chapter for Medincell October 9, 2026 1 WELTRUZA is a regi stered trade mark of Te va Pharmaceuti cal s USA, Inc.
Slide 2: Important Notice
IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING This presentation and the related conference call contain forward-looking statements, including statements regarding the Company’s expectations concerning: (i) the timing, progress and outcome of its clinical trials; (ii) the clinical
Slide 3: "Shift to Growth" Strategy: 3 Engines Firing in Parallel
“Shift to Growth” Strategy 3 Engines Firing in Parallel ABBVIE #1, PIPELINE & INNOVATION 03 OLANZAPINE LAI 02 WELTRUZA is a regi stered trade mark of Te va Pharmaceuti cal s USA, Inc. RISPERIDONE LAI 01 3
Slide 4: WELTRUZA: Transformational Milestone for Medincell
WELTRUZA : Transformational Milestone for Medincell Innovation impact Financial impact Platform validation First & only subcutaneous once-monthly olanzapine A new long-term A second FDA- LAI for the treatment of revenue stream approved product schizophrenia in adults WELTRUZA is a regi stered trade
Slide 5: A Severe Disease Burden, A Persistent Adherence Challenge
A Severe Disease Burden A Persistent Adherence Challenge Schizophrenia is a chronic, progressive and debilitating disorder ~1% 20–29 25–35% ~28.5 years of the global peak age of psychiatric of average life lost population of onset hospitalizations 67% of schizophrenia patients are non-adherent or of
Slide 6: Addressing the Adherence Challenge
Addressing the Adherence Challenge Missed doses can lead Preventing relapse Improved adherence to negative treatment helps preserve with LAIs is associated response and relapse1 long-term stability2 with lower relapse risk2 LAIs are at the core of schizophrenia innovation 1. Zacker C, Puckett JT, Ka
Slide 7: Strong Dynamics of LAI Penetration in Schizophrenia
Strong Dynamics of LAI Penetration in Schizophrenia +38% 18% 13% 2025 2030+ LAI penetration in total treated schizophrenia population, in % Source: LAI penetration based on IQVIA sales in Month of Therapy volume, with MIDAS (sales) dataset for EU and NDA Trx dataset for US / Teva’s Innovation Strate
Slide 8: ~300,000 U.S. Patients on Oral Olanzapine, the Initial Addressable Opportunity
~300,000 U.S. Patients on Oral Olanzapine, the Initial Addressable Opportunity ~2.2M Olanzapine is the most prescribed atypical oral people diagnosed with schizophrenia in the U.S. 1 antipsychotic in schizophrenia ~1.5M Established treatment option, including in more are treated with oral antipsycho
Slide 9: First Olanzapine LAI approved in the U.S. without post-injection monitoring
WELTRUZA is the first Olanzapine LAI approved in the U.S. without a post-injection monitoring requirement WELTRUZA is a regi stered trade mark of Te va Pharmaceuti cal s USA, Inc. 9
Slide 10: WELTRUZA is the First and Only Once-Monthly Subcutaneous Olanzapine LAI
WELTRUZA is the First and Only Once-Monthly Subcutaneous Olanzapine LAI Convenient, differentiated administration • Once-monthly subcutaneous long-acting injectable • No loading doses and no oral supplementation at initiation • Available in three once-monthly doses1 Demonstrated efficacy in Phase 3
Slide 11: Two Complementary LAIs Across the Care Pathway
Two Complementary LAIs Across the Care Pathway A broad share of U.S. schizophrenia patients now addressable UZED Y and WELTRUZA are registere d trademarks of Teva Pharmaceuticals USA, Inc. 11
Slide 12: A Major Untapped Antipsychotic LAI Opportunity
A Major Untapped Antipsychotic LAI Opportunity Risperidone* Olanzapine ~1/3 of treated patients on LAI Minimal LAI penetration to date LAI ORAL ORAL Oral: ~280,000 patients Oral: ~300,000 patients LAI: ~140,000 patients LAI: <200 patients * Risperidone and its metabolite paliperidone Charts represen
Slide 13: WELTRUZA Will Benefit from Teva's Proven Commercial Expertise
WELTRUZA Will Benefit from Teva's Proven Commercial Expertise Established Schizophrenia UZEDY® successful commercial market expertise launch experience infrastructure Differentiated product + Commercial execution 13
Slide 14: One Economic Model, Two Products
One Economic Model, Two Products UZEDY® WELTRUZA Mid- to high-single digit Mid- to high-single digit Royalties on all net sales on all net sales Up to $112m, including Up to $108 million, including Remaining milestones $4m upon US approval and $105m of commercial milestones $105m of commercial miles
Slide 15: U.S. Patent Portfolio
U.S. Patent Portfolio Latest listed patent expiration 2044 *Dates reflect currently listed U.S. patent expirations and may be subject to applicable adjustments, extensions and other factors. 15
Slide 16: WELTRUZA Opens a New Growth Chapter for Medincell
WELTRUZA Opens a New Growth Chapter for Medincell Addresses a major treatment gap and unlocks a significant ✓ market opportunity ✓ Creates a second long-term royalty stream Establishes Medincell’s platform as a proven engine for ✓ differentiated long-acting medicines WELTRUZA is a regi stered trade
Slide 17: The most transformative years in Medincell's History
The most transformative years in Medincell’s History 17